OIP — The Opportunity Intelligence PlatformOIP / Government Intelligence
Preparing the stored Government Intelligence discovery view.
OIP / Government Intelligence / Opportunity detail
Source: Stored live-derived Government dataNational Institutes of Health
OIP derived this review page from stored live-derived Government Intelligence source records. The official source and issuing agency remain authoritative.
Opportunity Intelligence Platform is an independent service and is not affiliated with or endorsed by the U.S. Government. Official notices, amendments, attachments, eligibility requirements, funding terms, and deadlines remain under source control.
OIP scores and explanations are informational and do not guarantee eligibility, suitability, compliance, contract award, or financial outcome.
State governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); Public and State controlled institutions of higher education; For profit organizations other than small businesses; Small businesses; City or township governments; Special district governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); County governments; Native American tribal governments (Federally recognized); Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Independent school districts
4 warning(s) require review.
Objective score, derived by OIP
Publication decision: Publish with warning
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) -- a Cooperative Agreement (Cooperative Agreement) issued by National Institutes of Health.
Objective Government score 71 for grants-gov-356717, computed from source evidence and Government scoring configuration.
novelty (insufficient_evidence): novelty could not be scored: no current Government source provides a reliable per-record signal for whether an opportunity is genuinely novel versus long-standing.
11 evidence record(s) support this pipeline result.
Next action: Review the official Grants.gov opportunity and follow the listed application package instructions.
95/100 · Ok
evidence_quality reflects a federal-source baseline plus completeness of deadline, funding value, eligibility, and official-source fields on this specific record.
90/100 · Ok
confidence reflects OIP's confidence in its own interpretation of this record's lifecycle and funding-value status, not confidence that any applicant will qualify.
78/100 · Ok
potential_value reflects the disclosed award ceiling or floor for this specific opportunity.
78/100 · Ok
urgency reflects the number of days remaining until the disclosed application deadline.
70/100 · Ok
difficulty reflects this opportunity's cooperative-agreement funding instrument, which typically involves substantial federal involvement and negotiation.
55/100 · Ok
time_required reflects the coordination and negotiation overhead typical of a cooperative-agreement funding instrument.
55/100 · Ok
capital_required reflects that cooperative agreements often require applicant cost-sharing as a matter of federal funding-mechanism convention; confirm the exact requirement in the official notice.
50/100 · Ok
risk reflects the number of material evidence gaps on this record (undisclosed value, missing deadline, unlisted eligibility, or a stale source date), not ordinary competitive uncertainty.
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
$.detail.opportunityTitle · Field Mapping · 98/100 confidence
356717 / PAR-25-075
$.detail.id · Field Mapping · 99/100 confidence
National Institutes of Health
$.detail.synopsis.agencyName · Field Mapping · 97/100 confidence
Cooperative Agreement
$.detail.synopsis.fundingInstruments · Field Mapping · 96/100 confidence
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.
$.detail.synopsis.synopsisDesc · Field Mapping · 94/100 confidence
Official source materials control eligibility, deadlines, amendments, attachments, and funding terms.
Open official sourceNo numeric value · Insufficient Evidence
novelty could not be scored: no current Government source provides a reliable per-record signal for whether an opportunity is genuinely novel versus long-standing.
2024-10-15T04:00:00.000Z
$.detail.synopsis.postingDate · Field Mapping · 96/100 confidence
2026-10-14T00:00:00.000Z
$.searchHit.closeDate · Field Mapping · 92/100 confidence
Applicant types: State governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Native American tribal organizations (other than Federally recognized tribal governments); Public and State controlled institutions of higher education; For profit organizations other than small businesses; Small businesses; City or township governments; Special district governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); County governments; Native American tribal governments (Federally recognized); Public housing authorities/Indian housing authorities; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Independent school districts
$.detail.synopsis.applicantTypes · Field Mapping · 94/100 confidence
250000.00
$.detail.synopsis.awardCeiling · Field Mapping · 92/100 confidence
2024-10-15T16:37:11.000Z
$.detail.synopsis.lastUpdatedDate · Field Mapping · 88/100 confidence
PAR-25-075-Full-Announcement.html
$.detail.synopsisAttachmentFolders[0].synopsisAttachments[0] · Field Mapping · 90/100 confidence